SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing heightened community debate as traders split between those viewing recent price action as a technical breakout opportunity and long-term skeptics who remain wary of its historical performance and lack of confirmed high-profile partnerships. The conversation is driven by a mix of market-wide altcoin momentum, renewed interest in Japan-based blockchain narratives, and speculative anticipation regarding the project's evolving ecosystem.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific (APAC). Its brands include Abercrombie and Hollister. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch ($ANF) is experiencing intense market volatility as investors weigh robust earnings beats and aggressive share buyback programs against concerns regarding tariff-related headwinds and cautious guidance. The stock remains a focal point for community discussion, with traders closely debating its low P/E valuation, the potential for short squeezes, and the company's ability to maintain momentum amidst a shifting retail landscape.

TOSHI

TOSHI is trending as investors speculate on potential exchange listings and its role in the Base ecosystem, with the community actively sharing bullish sentiment and accumulating tokens despite recent price volatility. Traders are closely monitoring key support levels and volume shifts, viewing current price action as a coiling phase ahead of an anticipated breakout.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is experiencing significant market volatility and active investor debate as it approaches its earnings report, with sentiment split between those bullish on the company's long-term expansion into AI and logistics and those concerned about consumer spending habits and high valuations. The community is heavily focused on the stock's recent price swings and whether the platform can maintain its growth narrative amidst stiff competition and broader economic pressures.

Hormuz Toll Fund (HTF) is a community-driven SPL token deployed on the Solana blockchain. The project takes its name and visual identity from the Strait of Hormuz, the maritime corridor through which a significant share of global seaborne crude oil transits, and adopts an energy and shipping-toll motif as the basis for its branding and community culture. Despite the word "Fund" in its name, HTF is not an investment fund, security, or pooled investment vehicle, and the project holds no physical commodity, oil contracts, or shipping rights of any kind. It is not affiliated with any government, maritime authority, or shipping entity. The token follows the standard Solana SPL fungible token model and trades on Solana-native decentralized exchanges with all transfers and balances publicly verifiable on-chain.

Hormuz Toll Fund

Hormuz Toll Fund is gaining traction as traders speculate on the project's long-term utility and potential for higher time frame growth.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad is seeing renewed market attention and high social media engagement as investors highlight its cultural persistence and long-term community dedication. The community is buzzing over its recent expansion into consumer health products, fueling active discussions about its potential for long-term growth as a major memecoin contender.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is attracting significant attention as investors monitor its lead drug candidate, ivonescimab, which is undergoing an FDA BLA review with a decision expected later this year. The community remains highly focused on the company's clinical pipeline and upcoming ASCO presentation, with many viewing the stock's recent volatility as a consolidation phase before potentially impactful regulatory and trial milestones.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos is experiencing heavy bearish sentiment and community frustration, with many users labeling it a "pump and dump" and questioning its long-term viability given its significant year-to-date losses. While some investors remain focused on the 15% APY staking rewards as a potential long-term play, the broader community discourse is dominated by disappointment over the token's inability to decouple from Bitcoin's volatility.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI remains a focal point for the investment community as market participants actively debate its long-term potential in precision medicine against near-term volatility and institutional selling pressure. While technical traders highlight the stock's coiling price action and critical support levels, the broader conversation centers on its growing pharma partnerships and the ongoing divide between retail bulls betting on AI-driven data dominance and skeptics cautious of recent dilution and valuation concerns.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is trending as investors react to a significant 15-year, $9.8 billion data center lease agreement, signaling a major strategic pivot from Bitcoin mining toward AI-focused digital infrastructure. The community is actively debating the stock's valuation and long-term sustainability, weighing the company's aggressive growth trajectory and institutional backing against recent earnings volatility and broader market uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised

MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings

Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +3.47% and +8.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the first quarter 2026 and provided a business update. 2026 is off to an excellent...

Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week High After Analyst Upgrade

Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week High on Analyst Upgrade...

<ul class="summary-bullets"><li>In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases.&nbsp;</li><li>The company added that it now expects topline data from a separate study of volixibat in primary biliary cholangitis in the first quarter of 2027.</li></ul> Shares of Mirum Pharmaceuticals, Inc. (MIRM) closed 10% higher on Monday, marking its best day since mid-December, after the company said that its investigational drug volixibat met the primary endpoint in a mid-stage study in patients with a rare liver disease.Primary Sclerosing Cholangitis (PSC) is a chronic, progressive, and rare liver disease characterized by inflammation, scarring, and narrowing of the bile ducts. In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases.In the primary analysis cohort of 111 patients with moderate-to-severe itch at baseline, volixibat 20 mg twice daily produced a 2.72-point improvement from baseline on a standardized scale, compared with a 1.08-point improvement for placebo, the company said. Statistically significant itch relief was observed as early as two weeks after starting therapy and was also seen in the secondary cohort of patients with mild itch, it added.Severe adverse events associated with the drug in the trial consisted mainly of gastrointestinal side effects and elevations in liver laboratory values such as ALT and bilirubin, the company said.<h2 class="st-heading-2">FDA Approval And Process</h2>The results position volixibat as a potential approved therapy for the severe itching that is one of the most burdensome symptoms of PSC, a rare and progressive liver disease with no approved treatments, according to Mirum’s chief medical officer Joanne Quan.Mirum said it has scheduled a pre-New Drug Application meeting with the U.S. Food and Drug Administration for this summer and plans to submit an NDA in the second half of 2026. The company added that it now expects topline data from a separate study of volixibat in primary biliary cholangitis in the first quarter of 2027.<h2 class="st-heading-2">How Did MIRM Retail Traders React?</h2>On Stocktwits, retail sentiment around MIRM jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A Stocktwits user voiced optimism for a buyout at up $160/share price.<stembedurl>https://www.stocktwits.com/BZAJDEL/message/652215094</stembedurl><a href="https://stocktwits.com/symbol/MIRM">MIRM stock </a>has gained about 140% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-warns-of-no-fair-fight-with-chinese-evs-while-byd-dwarfs-its-april-output/cZQu5XdReJq">Ford Warns Of ‘No Fair Fight’ With Chinese EVs While BYD Dwarfs Its April Output</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Mirum Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium

Mirum said it has scheduled a pre-New Drug Application meeting with the U.S. Food and Drug Administration for this summer to discuss its drug volixibat in the treatment of Primary Sclerosing Cholangitis. 

Equity

Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down - What's Next?

Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down - Here's Why...

Mirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs Placebo

Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase IIb VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC) met its primary endpoint, showing a statistically significant reduction in cholestatic pruritus compared with placebo, according to executives on the company's busin...

HC Wainwright Forecasts Strong Price Appreciation for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

HC Wainwright lifted their price objective on Mirum Pharmaceuticals from $150.00 to $175.00 and gave the company a "buy" rating in a report on Monday...

Mirum Pharma's Phase 2b Study Of Volixibat For Sclerosing Cholangitis Meets End Point, Shares Gain

(RTTNews) - Mirum Pharmaceuticals, Inc. (MIRM), Monday said that its VISTAS Phase 2b study evaluating Volixibat met primary endpoint in patients with primary sclerosing cholangitis or PSC. The...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Mirum Pharmaceuticals Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

MIRM
Mirum Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest MIRM News

MIRMMirum Pharmaceuticals Inc